Ondansetron Orally Disintegrating Tablets
SPE2D2-25-R-0018 · DEPT OF DEFENSE
A PHARMACEUTICAL PREPARATION MANUFACTURING solicitation, with responses due 2026-04-22. AwardCast estimates what this specific solicitation will close for, before you bid.
What's being bought
Amendment 0004 issued since this procurement is using the procedures of 41 U.S.C. 1901, as implemented by Class Deviation 2026-O0028 Revolutionary Federal Acquisition Regulation (FAR) Overhaul Part 12, Defense FAR Supplement (DFARS) Part 212 and Revolutionary FAR Overhaul Part 12.201-1. See updated
Comparable recent awards in PHARMACEUTICAL PREPARATION MANUFACTURING
| Winner | Award value | Offers | Date |
|---|---|---|---|
| THERACOM, L.L.C. | $38K | 1 | 2026-07-02 |
| REGIMED MEDICAL | $293K | 7 | 2026-07-02 |
| SRI INTERNATIONAL | $49.9M | 7 | 2026-07-02 |
| PRIORITY HEALTHCARE DISTRIBUTION INC | $16K | 1 | 2026-07-02 |
| COVERMYMEDS PHARMACY LLC | $16K | 1 | 2026-07-02 |
Questions
What is solicitation SPE2D2-25-R-0018?
Ondansetron Orally Disintegrating Tablets, issued by DEPT OF DEFENSE, under NAICS 325412 (PHARMACEUTICAL PREPARATION MANUFACTURING). Responses are due 2026-04-22.
What do similar contracts close for?
Comparable closed awards in this category ran from $16K to $49.9M, across 5 awards shown above. Those are historical results, not a forecast for this solicitation.
Explore the market
Forecast Report — what a specific solicitation will close for: the predicted price range, the competition to expect, and comparable awards already closed. Before you price your bid.
Every forecast is scored against the real award once it becomes public. See the track record.
Closed awards from public federal data, not the forecast. One email, no account.
Or get the forecast for this solicitation — $49, one report.